A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 269
Comprehensive Pages
- 8
Geographic and Economic Breakouts
- 5
Year Market Forecasts
- 52
Diseases Analyzed
2025 Cornea Products Market Report: Global Analysis for 2024 to 2030, December, 2025
The “2025 Cornea Products Market Report” delivers an in-depth analysis of the global cornea market, highlighting the latest advances in transplantation, crosslinking, and therapeutic devices aimed at restoring and preserving vision. The report estimates disease prevalence across six major corneal conditions and examines evolving treatment approaches, including cornea transplants, therapeutic lenses, phototherapeutic keratectomy (PTK), intrastromal ring segments, and corneal crosslinking.
It also explores the global ecosystem that supports cornea care—spanning organ donation systems, regulatory environments, and the pivotal roles of cornea specialists, eye banks, and nonprofit organizations.
This 2025 edition evaluates more than 70 products from over 50 companies, with forecasts for unit demand and revenue growth through 2030. It features analysis of emerging pipeline technologies yet to generate revenue and profiles 12 leading market participants shaping the future of cornea treatment.
Latest Industry News & Trends
5/8/2026
BreakingDealsGlaucomaPharmaRetina
Bayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 Billion
German drugmaker Bayer announced May 6 that it would acquire Perfuse Therapeutics in a deal worth up to $2.45 billion. Perfuse, of South San Francisco, California, is advancing PER-001 for glaucoma...
5/8/2026
BiosimilarsBreakingCataractIOLRetinaRevenueSurgicalThyroid Eye Disease
Quarterly Ophthalmic Revenue Roundup for Alcon, Amgen, Hoya, Ocular Therapeutix, and Xbrane
Alcon reported May 6 that its Q1-2026 net sales were $2.69 billion, a 10 percent increase (+6 percent cc) over $2.45 billion in Q1-2025. Surgical net sales totaled $1.46 billion, consisting of $438...
5/8/2026
BreakingDeviceEuropeRetinaSurgical
Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe
Bausch + Lomb announced May 7 the European launch of the Bi-Blade+ dual-port vitrectomy cutter on the Stellaris Elite dual-function cataract and vitrectomy system. The Bi-Blade+ now offers 25 thous...
5/8/2026
BiosimilarsBreakingRegulationRetina
Xbrane Resubmits BLA to US FDA for Lucentis Biosimilar
Sweden’s Xbrane Biopharma announced April 30 that it had resubmitted the biologics license application (BLA) for its Lucentis (ranibizumab) biosimilar to the US FDA. A complete response letter from...
5/8/2026
BreakingDealsRetina
Novelty Nobility Taps AGC Biologics to Help Advance Bispecific Retinal Candidate
South Korea’s Novelty Nobility announced May 4 that it had expanded its manufacturing agreement with AGC Biologics to advance retinal disease candidate NN4101 through process development and GMP ma...
5/8/2026
BreakingDealsEuropeRetina
Kubota Vision, Laboratoires Kôl Team Up on Compassionate Use of Stargardt Candidate
Kubota Vision and Laboratoires Kôl announced May 4 that they had signed a supply and licensing agreement to bring emixustat hydrochloride, an oral treatment candidate for Stargardt disease, to pati...
5/8/2026
BreakingClinical TrialRegulationRetina
US FDA Accepts Opus’ LCA5 Gene Therapy Candidate into New Rare Disease Program
Opus Genetics announced May 4 that the US FDA had accepted OPGx-LCA5, a gene therapy candidate targeting Leber congenital amaurosis type 5, into the new Rare Disease Evidence Principles (RDEP) prog...
5/1/2026
BreakingCataractEquipmentEuropeRegulationRetinaSurgical
BVI Announces Full CE Marking for its Virtuoso Platforms
BVI Medical reported April 20 that itsVirtuoso cataract-only and dual-function cataract-vitrectomy platforms had gained CE marking under the new European Union Medical Device Regulation (MDR). The ...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.